GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer

Abrams, 2021, GSK-3β can regulate the sensitivity of MIA-PaCa-2 pancreatic and MCF-7 breast cancer cells to chemotherapeutic drugs, targeted therapeutics and nutraceuticals, Cells, 10, 816, 10.3390/cells10040816 Aghdassi, 2012, Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer, Gut, 61, 439, 10.1136/gutjnl-2011-300060 Arlt, 2003, Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death, Oncogene, 22, 3243, 10.1038/sj.onc.1206390 Arora, 2013, An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4, J. Biol. Chem., 288, 21197, 10.1074/jbc.M113.484576 Aung, 2018, Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial, Clin. Cancer Res., 24, 1344, 10.1158/1078-0432.CCR-17-2994 Bailey, 2016, Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, 531, 47, 10.1038/nature16965 Bang, 2013, GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB, Cancer Discov., 3, 690, 10.1158/2159-8290.CD-12-0541 Baudino, 2015, Targeted cancer therapy: the next generation of cancer treatment, Curr. Drug Discov. Technol., 12, 3, 10.2174/1570163812666150602144310 Baumgart, 2016, GSK-3β governs inflammation-induced NFATc2 signaling hubs to promote pancreatic cancer progression, Mol. Cancer Ther., 15, 491, 10.1158/1535-7163.MCT-15-0309 Ben-Josef, 2015, Williams Glycogen synthase kinase 3 beta predicts survival in resected adenocarcinoma of the pancreas, Clin. Cancer Res., 21, 5612, 10.1158/1078-0432.CCR-15-0789 Beurel, 2015, Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases, Pharmacol. Ther., 0, 114, 10.1016/j.pharmthera.2014.11.016 Bhat, 2003, Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418, J. Biol. Chem., 278, 45937, 10.1074/jbc.M306268200 Bijur, 2003, Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria, Neuroreport, 14, 2415, 10.1097/00001756-200312190-00025 Binenbaum, 2015, Gemcitabine resistance in pancreatic ductal adenocarcinoma, Drug Resist. Updat., 23, 55, 10.1016/j.drup.2015.10.002 Bowden, 2000, Efficacy of lithium in mania and maintenance therapy of bipolar disorder, J. Clin. Psychiatry, 61, 35 Boyd, 2021, Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment, Semin. Cancer Biol., 15 Brunton, 2020, HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer, Cell Rep., 31, 107625, 10.1016/j.celrep.2020.107625 Caparello, 2016, FOLFIRINOX and translational studies: towards personalized therapy in pancreatic cancer, World J. Gastroenterol., 22, 6987, 10.3748/wjg.v22.i31.6987 Carbone, 2021, 1,2,4-oxadiazole topsentin analogs with antiproliferative activity against pancreatic cancer cells, targeting GSK3β kinase, ChemMedChem, 16, 537, 10.1002/cmdc.202000752 Carneiro, 2020, Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors, J. Clin. Oncol., 38, 3507, 10.1200/JCO.2020.38.15_suppl.3507 Carter, 2014, Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth, Cancer Biol. Ther., 15, 510, 10.4161/cbt.28015 Cervello, 2012, Targeted therapy for epatocellular carcinoma: novel agents on the horizon, Oncotarget, 3, 236, 10.18632/oncotarget.466 Chan-Seng-Yue, 2020, Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution, Nat. Genet., 52, 231, 10.1038/s41588-019-0566-9 Chen, 2016, Role of glycogen synthase kinase-3β inhibitor AZD1080 in ovarian cancer, Drug Des. Devel. Ther., 10, 1225 Christenson, 2016, Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future, Lancet Oncol., 21, e135, 10.1016/S1470-2045(19)30795-8 Cohen, 1998, Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment, Med. Oncol. Northwood Lond. Engl., 15, 32, 10.1007/BF02787342 Collisson, 2019, Molecular subtypes of pancreatic cancer, Nat. Rev. Gastroenterol. Hepatol., 16, 207, 10.1038/s41575-019-0109-y Coppola, 2017, A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer, Drug Resist. Update, 31, 43, 10.1016/j.drup.2017.07.001 Cormier, 2017, Recent advances in understanding the cellular roles of GSK-3, F1000Research, 6 Cox, 2014, Drugging the undruggable Ras: mission possible? Nat, Rev. Drug Discov., 13, 828, 10.1038/nrd4389 Dajani, 2003, Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex, EMBO J., 22, 494, 10.1093/emboj/cdg068 De Sarno, 2002, Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium, Neuropharmacology, 43, 1158, 10.1016/S0028-3908(02)00215-0 Demarchi, 2003, Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability, J. Biol. Chem., 278, 39583, 10.1074/jbc.M305676200 Dewi, 2018, Colorectal cancer cells require glycogen synthase kinase-3β for sustaining mitosis via translocated promoter region (TPR)-dynein interaction, Oncotarget, 9, 13337, 10.18632/oncotarget.24344 Ding, 2020, Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer, Expert Opin. Ther. Targets, 24, 417, 10.1080/14728222.2020.1743681 Ding, 2017, Glycogen synthase kinase-3β ablation limits pancreatitis-induced acinar-to-ductal metaplasia, J. Pathol., 243, 65, 10.1002/path.4928 Ding, 2019, Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to chemotherapy by abrogating the TopBP1/ATR-mediated DNA damage response, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 25, 6452, 10.1158/1078-0432.CCR-19-0799 Doble, 2003, GSK-3: tricks of the trade for a multi-tasking kinase, J. Cell. Sci., 116, 1175, 10.1242/jcs.00384 Doble, 2007, Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions, Cells Tissues Organs (Print), 185, 73, 10.1159/000101306 Domínguez, 2012, Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib, J. Biol. Chem., 287, 893, 10.1074/jbc.M111.306472 Domoto, 2016, Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapy, Cancer Sci., 107, 1363, 10.1111/cas.13028 Domoto, 2020, Glycogen synthase kinase 3β in cancer biology and treatment, Cells, 9 Downward, 2015, RAS synthetic lethal screens revisited: still seeking the elusive prize?, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 21, 1802, 10.1158/1078-0432.CCR-14-2180 Duda, 2020, Targeting GSK3 and associated signaling pathways involved in cancer, Cells, 9 Edderkaoui, 2018, An inhibitor of GSK3B and HDACs kills pancreatic cancer cells and slows pancreatic tumor growth and metastasis in mice, Gastroenterology, 155, 10.1053/j.gastro.2018.08.028 El Hassouni, 2019, Pharmacogenetics of treatments for pancreatic cancer, Expert Opin. Drug Metab. Toxicol., 15, 437, 10.1080/17425255.2019.1620731 Eldar-Finkelman, 2011, GSK-3 inhibitors: preclinical and clinical focus on CNS, Front. Mol. Neurosci., 4 Elmaci, 2016, A metabolic inhibitory cocktail for grave cancers: metformin, pioglitazone and Lithium combination in treatment of pancreatic cancer and glioblastoma multiforme, Biochem. Genet., 54, 573, 10.1007/s10528-016-9754-9 Eser, 2014, Oncogenic KRAS signalling in pancreatic cancer, Br. J. Cancer, 111, 817, 10.1038/bjc.2014.215 Fang, 2000, Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A, Proc. Natl. Acad. Sci. U. S. A., 97, 11960, 10.1073/pnas.220413597 Firuzi, 2019, Role of c-MET inhibitors in overcoming drug resistance in spheroid models of primary human pancreatic cancer and stellate cells, Cancers (Basel), 11, 638, 10.3390/cancers11050638 Fitzgerald, 2015, Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells, Adv. Biol. Regul., 59, 65, 10.1016/j.jbior.2015.06.003 Fleming, 2005, Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy, Mol. Cancer Res. MCR, 3, 413, 10.1158/1541-7786.MCR-04-0206 Foltz, 2002, Glycogen synthase kinase-3beta modulates notch signaling and stability, Curr. Biol. CB, 12, 1006, 10.1016/S0960-9822(02)00888-6 Frame, 2001, A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation, Mol. Cell, 7, 1321, 10.1016/S1097-2765(01)00253-2 Freland, 2012, Inhibition of GSK3 by lithium, from single molecules to signaling networks, Front. Mol. Neurosci., 5 Gaisina, 2009, From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells, J. Med. Chem., 52, 1853, 10.1021/jm801317h Galluzzi, 2015, Autophagy in malignant transformation and cancer progression, EMBO J., 34, 856, 10.15252/embj.201490784 Gao, 2013, Identification and analysis of glycogen synthase kinase 3 beta1 interactome, Cell Biol. Int., 37, 768, 10.1002/cbin.10095 Garcea, 2007, Glycogen synthase kinase-3 beta; a new target in pancreatic cancer, Curr. Cancer Drug Targets, 7, 209, 10.2174/156800907780618266 Garcia-Sampedro, 2021, The state-of-the-Art of phase II/III clinical trials for targeted pancreatic cancer therapies, J. Clin. Med., 10, 566, 10.3390/jcm10040566 Giovannetti, 2014, CYB5A role in pancreatic cancer prognosis and autophagy modulation, JNCI – J. Natl. Cancer Inst., 106, djt346, 10.1093/jnci/djt346 Giovannetti, 2017, Never let it go: stopping key mechanisms underlying metastasis to fight pancreatic cancer, Semin. Cancer Biol., 44, 43, 10.1016/j.semcancer.2017.04.006 Gomez Mellado, 2015, Unraveling the complexity of autophagy: potential therapeutic applications in Pancreatic Ductal Adenocarcinoma, Sem Cancer Biol., 35, 11, 10.1016/j.semcancer.2015.09.011 Gray, 2015, A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin, Invest. New Drugs, 33, 1187, 10.1007/s10637-015-0278-7 Guo, 2019, 6-bromoindirubin-3′-Oxime (6BIO) suppresses the mTOR pathway, promotes autophagy, and exerts anti-aging effects in rodent liver, Front. Pharmacol., 10 Hermida, 2017, GSK3 and its interactions with the PI3K/AKT/mTOR signalling network, Adv. Biol. Regul., 65, 5, 10.1016/j.jbior.2017.06.003 Hill, 2020, Pancreatic cancer Hoeflich, 2000, Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation, Nature, 406, 86, 10.1038/35017574 Holcomb, 2008, The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy, Pancreas, 36, 225, 10.1097/MPA.0b013e31815b3207 Hooper, 2008, The GSK3 hypothesis of Alzheimer’s disease, J. Neurochem., 104, 1433, 10.1111/j.1471-4159.2007.05194.x Horrigan, 2020, A phase 2 study of AMO-02 (Tideglusib) in congenital and childhood-onset myotonic dystrophy type 1 (DM1), Pediatr. Neurol., 112, 84, 10.1016/j.pediatrneurol.2020.08.001 Hughes, 1993, Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation, EMBO J., 12, 803, 10.1002/j.1460-2075.1993.tb05715.x Ireland, 2016, Chemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factors, Cancer Res., 76, 6851, 10.1158/0008-5472.CAN-16-1201 Johnson, 1983, The first era of lithium in medicine. An historical note, Pharmacopsychiatria, 16, 61, 10.1055/s-2007-1017450 Kaidanovich-Beilin, 2011, GSK-3: functional insights from cell biology and animal models, Front. Mol. Neurosci., 4 Kaltschmidt, 2018, Subunit-specific role of NF-κB in cancer, Biomedicines, 6, 44, 10.3390/biomedicines6020044 Kaur, 2017, A combination of MUC5AC and CA19-9 improves the diagnosis of pancreatic cancer: a multicenter study, Am. J. Gastroenterol., 112, 172, 10.1038/ajg.2016.482 Kazi, 2018, GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors, Nat. Commun., 9, 5154, 10.1038/s41467-018-07644-6 Kim, 2000, Overexpression of beta-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators, Mol. Biol. Cell, 11, 3509, 10.1091/mbc.11.10.3509 Kitano, 2013, Aberrant glycogen synthase kinase 3β is involved in pancreatic Cancer cell invasion and resistance to therapy, PLoS One, 8 Kockeritz, 2006, Glycogen synthase kinase-3--an overview of an over-achieving protein kinase, Curr. Drug Targets, 7, 1377, 10.2174/1389450110607011377 Komiya, 2008, Wnt signal transduction pathways, Organogenesis, 4, 68, 10.4161/org.4.2.5851 Korur, 2009, GSK3beta regulates differentiation and growth arrest in glioblastoma, PLoS One, 4, e7443, 10.1371/journal.pone.0007443 Kotliarova, 2008, Glycogen synthase kinase 3 inhibition induces glioma cell death through c-MYC, NF-κB and glucose regulation, Cancer Res., 68, 6643, 10.1158/0008-5472.CAN-08-0850 Krause, 2002, Signalling pathways and combinatory effects of insulin and amino acids in isolated rat hepatocytes, Eur. J. Biochem., 269, 3742, 10.1046/j.1432-1033.2002.03069.x Kroon, 2014, Glycogen synthase kinase-3β inhibition depletes the population of prostate cancer stem/progenitor-like cells and attenuates metastatic growth, Oncotarget, 5, 8986, 10.18632/oncotarget.1510 Kunnimalaiyaan, 2015, Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression, HPB, 17, 770, 10.1111/hpb.12442 Kuroki, 2019, 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer, Sci. Rep., 9, 19977, 10.1038/s41598-019-56461-4 Le Large, 2017, Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies, Semin. Cancer Biol., 44, 153, 10.1016/j.semcancer.2017.03.008 Le Large, 2020, Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets, JCI Insight, 5, 138290, 10.1172/jci.insight.138290 Le Large, 2021, Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma, J. Exp. Clin. Cancer Res., 40, 91, 10.1186/s13046-021-01892-z Li, 2000, Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta, Mol. Cell. Biol., 20, 9356, 10.1128/MCB.20.24.9356-9363.2000 Li, 2018, Fisetin inhibited growth and metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via PTEN/Akt/GSK3β signal pathway, Front. Pharmacol., 9 Liang, 2003, Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression, Cell Cycle Georget. Tex, 2, 339 Lin, 2015, The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies, Nat. Genet., 47, 250, 10.1038/ng.3218 Liptay, 2003, Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer, Int. J. Cancer, 105, 735, 10.1002/ijc.11081 Liu, 2017, GSK-3β inhibitor 6-bromo-indirubin-3’-oxime promotes both adhesive activity and drug resistance in colorectal cancer cells, Int. J. Oncol., 51, 1821, 10.3892/ijo.2017.4163 Lomberk, 2018, Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes, Nat. Commun., 9, 1978, 10.1038/s41467-018-04383-6 Lovestone, 2015, A phase II trial of tideglusib in Alzheimer’s disease, J. Alzheimers Dis. JAD, 45, 75, 10.3233/JAD-141959 Mamaghani, 2009, Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy, BMC Cancer, 9, 132, 10.1186/1471-2407-9-132 Mamaghani, 2012, Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis, PLoS One, 7, 10.1371/journal.pone.0041102 Marchand, 2012, Inhibition of glycogen synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through JNK-dependent mechanisms, Carcinogenesis, 33, 529, 10.1093/carcin/bgr309 Marchand, 2015, Glycogen synthase Kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells*, J. Biol. Chem., 290, 5592, 10.1074/jbc.M114.616714 Martelli, 2021, GSK-3: a multifaceted player in acute leukemias, Leukemia, 1 Martinsson, 2016, Lithium treatment and cancer incidence in bipolar disorder, Bipolar Disord., 18, 33, 10.1111/bdi.12361 Massihnia, 2017, Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer, J. Hematol. Oncol., 10, 9, 10.1186/s13045-016-0371-1 McCubrey, 2012, Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance, Oncotarget, 3, 1068, 10.18632/oncotarget.659 McCubrey, 2012, Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response, Oncotarget, 3, 954, 10.18632/oncotarget.652 McCubrey, 2014, Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy, Adv. Biol. Regul., 54, 176, 10.1016/j.jbior.2013.09.013 McCubrey, 2016, Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer, Biochim. Biophys. Acta, 1863, 2942, 10.1016/j.bbamcr.2016.09.004 Meijer, 2003, GSK-3-selective inhibitors derived from Tyrian purple indirubins, Chem. Biol., 10, 1255, 10.1016/j.chembiol.2003.11.010 Meijer, 2020, Plasma miR-181a-5p down-regulation predicts response and improved survival after FOLFIRINOX in pancreatic ductal adenocarcinoma, Ann Surgery., 271, 1137, 10.1097/SLA.0000000000003084 Melisi, 2011, Modulation of pancreatic cancer chemoresistance by inhibition of TAK1, J. Natl. Cancer Inst., 103, 1190, 10.1093/jnci/djr243 Meng, 2018, Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling, Oncogene, 37, 5843, 10.1038/s41388-018-0392-z Miyashita, 2009, An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta, Anticancer Agents Med. Chem., 9, 1114, 10.2174/187152009789734982 Mora, 2002, Lithium blocks the PKB and GSK3 dephosphorylation induced by ceramide through protein phosphatase-2A, Cell. Signal., 14, 557, 10.1016/S0898-6568(01)00282-0 Nagini, 2019, Glycogen synthase kinases: moonlighting proteins with theranostic potential in cancer, Semin. Cancer Biol., 56, 25, 10.1016/j.semcancer.2017.12.010 Namba, 2015, Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway, Cell Death Dis., 6, e1795, 10.1038/cddis.2015.172 NCT01287520, 2018, Eli Lilly and Company NCT01632306, 2019, Eli Lilly and Company NCT03678883, 2021, Actuate Therapeutics Inc Okamoto, 2007, NF-kappa B signaling and carcinogenesis, Curr. Pharm. Des., 13, 447, 10.2174/138161207780162944 Ougolkov, 2005, Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells, Cancer Res., 65, 2076, 10.1158/0008-5472.CAN-04-3642 Ougolkov, 2006, Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation, Clin. Cancer Res., 12, 5074, 10.1158/1078-0432.CCR-06-0196 Pasquali, 2010, Intracellular pathways underlying the effects of lithium, Behav. Pharmacol., 21, 473, 10.1097/FBP.0b013e32833da5da Peng, 2013, Lithium inhibits tumorigenic potential of PDA cells through targeting Hedgehog-GLI signaling pathway, PLoS One, 8, 10.1371/journal.pone.0061457 Phiel, 2001, Molecular targets of lithium action, Annu. Rev. Pharmacol. Toxicol., 41, 789, 10.1146/annurev.pharmtox.41.1.789 Pusceddu, 2019, Comparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis, Cancers, 11 Rahib, 2014, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res., 74, 2913, 10.1158/0008-5472.CAN-14-0155 Randazzo, 2020, “Open Sesame?”: impact of biomarker role and molecular mechanisms influencing the human equilibrative nucleoside transporter-1 in the uptake and cytotoxicity of gemcitabine in pancreatic cancer, Cancers, 12, 3206, 10.3390/cancers12113206 Riobó, 2006, Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling, Proc. Natl. Acad. Sci. U. S. A., 103, 4505, 10.1073/pnas.0504337103 Rizzieri, 2016, An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia, Leuk. Lymphoma, 57, 1800, 10.3109/10428194.2015.1122781 Ryves, 2001, Lithium inhibits glycogen synthase kinase-3 by competition for magnesium, Biochem. Biophys. Res. Commun., 280, 720, 10.1006/bbrc.2000.4169 Saiki, 2012, DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells, Biochem. Biophys. Res. Commun., 421, 98, 10.1016/j.bbrc.2012.03.122 Santoro, 2020, Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer, Mol. Cancer Ther., 19, 247, 10.1158/1535-7163.MCT-19-0270 Sarantis, 2020, Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy, World J. Gastrointest. Oncol., 12, 173, 10.4251/wjgo.v12.i2.173 Saraswati, 2018, Glycogen synthase kinase-3 and its inhibitors: potential target for various therapeutic conditions, Eur. J. Med. Chem., 144, 843, 10.1016/j.ejmech.2017.11.103 Seino, 2018, Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression, Cell Stem Cell, 22, 10.1016/j.stem.2017.12.009 Shimasaki, 2012, Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine, J. Gastroenterol., 47, 321, 10.1007/s00535-011-0484-9 Shin, 2011, Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation, Proc. Natl. Acad. Sci. U. S. A., 108, E1204, 10.1073/pnas.1110195108 Shukla, 2017, MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer, Cancer Cell, 32, 10.1016/j.ccell.2017.08.008 Siegel, 2021, Cancer statistics, 2021, CA Cancer J. Clin., 71, 7, 10.3322/caac.21654 Singh, 1995, Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline-dependent protein kinases, FEBS Lett., 358, 4, 10.1016/0014-5793(94)01383-C Song, 2010, Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth, Exp. Hematol., 38 Stamos, 2014, Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6, eLife, 3, 10.7554/eLife.01998 Sun, 2016, GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells, Prostate, 76, 172, 10.1002/pros.23106 Supadmanaba, 2021, Organotypic-liver slide culture systems to explore the role of extracellular vesicles in pancreatic cancer metastatic behavior and guide new therapeutic approaches, Expert Opin. Drug Metab. Toxicol., 21, 1 Sutherland, 2011, What are the bona fide GSK3 substrates?, Int. J. Alzheimers Dis., 2011, 505607 ter Haar, 2001, Structure of GSK3beta reveals a primed phosphorylation mechanism, Nat. Struct. Biol., 8, 593, 10.1038/89624 Tran, 2017, Modulating the wnt signaling pathway with small molecules, Protein Sci. Publ. Protein Soc., 26, 650, 10.1002/pro.3122 Uehara, 2020, Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer, Cancer Sci., 111, 4405, 10.1111/cas.14668 Vulpetti, 2005, Structure-based approaches to improve selectivity: CDK2-GSK3beta binding site analysis, J. Chem. Inf. Model., 45, 1282, 10.1021/ci0500280 Walz, 2017, Molecular pathways: revisiting glycogen synthase Kinase-3β as a target for the treatment of cancer, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 23, 1891, 10.1158/1078-0432.CCR-15-2240 Waters, 2018, KRAS: the critical driver and therapeutic target for pancreatic cancer, Cold SpringHarb. Perspect. Med., 8 Webster, 2000, Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding, Genes Chromosomes Cancer, 28, 443, 10.1002/1098-2264(200008)28:4<443::AID-GCC10>3.0.CO;2-D Wilson, 2008, Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer, Cancer Res., 68, 8156, 10.1158/0008-5472.CAN-08-1061 Woodgett, 1990, Molecular cloning and expression of glycogen synthase kinase-3/factor A, EMBO J., 9, 2431, 10.1002/j.1460-2075.1990.tb07419.x Wu, 2010, GSK3: a multifaceted kinase in Wnt signaling, Trends Biochem. Sci., 35, 161, 10.1016/j.tibs.2009.10.002 Xia, 2014, NF-κB, an active player in human cancers, Cancer Immunol. Res., 2, 823, 10.1158/2326-6066.CIR-14-0112 Xie, 2017, GSK-3 inhibition suppresses lung cancer cell survival, metastasis and proliferation through down-regulation the phosphorylation sites of CAP1, Eur. Respir. J., 50 Xu, 2009, Regulation of protein stability by GSK3 mediated phosphorylation, Cell Cycle Georget. Tex, 8, 4032, 10.4161/cc.8.24.10111 Yang, 2011, A critical role for autophagy in pancreatic cancer, Autophagy, 7, 912, 10.4161/auto.7.8.15762 Yang, 2011, Pancreatic cancers require autophagy for tumor growth, Genes Dev., 25, 717, 10.1101/gad.2016111 Yoneyama, 2015, Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones, Anticancer Drugs, 26, 90, 10.1097/CAD.0000000000000165 Yoshino, 2015, Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells, Sci. Rep., 5, 13249, 10.1038/srep13249 Yu, 2012, RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis, Nature, 487, 510, 10.1038/nature11217 Zamek-Gliszczynski, 2013, Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure, Drug Metab. Dispos. Biol. Fate Chem., 41, 714, 10.1124/dmd.112.048488 Zeng, 2019, Chemoresistance in pancreatic cancer, Int. J. Mol. Sci., 20 Zhang, 2003, Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3, J. Biol. Chem., 278, 33067, 10.1074/jbc.M212635200 Zhang, 2011, Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer, Oncogene, 30, 3705, 10.1038/onc.2011.90 Zhang, 2014, Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells, Cell Death Dis., 5, e1142, 10.1038/cddis.2014.102 Zhang, 2017, 6BIO enhances oligonucleotide activity in cells: a potential combinatorial anti-androgen receptor therapy in prostate cancer cells, Mol. Ther., 25, 79, 10.1016/j.ymthe.2016.10.017 Zhitomirsky, 2015, Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance, Oncotarget, 6, 1143, 10.18632/oncotarget.2732 Zhitomirsky, 2016, Lysosomes as mediators of drug resistance in cancer, Drug Resist. Updat., 24, 23, 10.1016/j.drup.2015.11.004 Zhitomirsky, 2018, Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity, Cell Death Dis., 9, 1191, 10.1038/s41419-018-1227-0 Zhou, 2017, Early detection of pancreatic cancer: where are we now and where are we going?, Int. J. Cancer, 141, 231, 10.1002/ijc.30670 Zhu, 2010, The human glioma-associated oncogene homolog 1 (GLI1) family of transcription factors in gene regulation and diseases, Curr. Genomics, 11, 238, 10.2174/138920210791233108